Cancer Immunotherapeutics Program ABSTRACT The mission of the Cancer Immunotherapeutics (CI) Program is to develop novel immunotherapy interventions that harness patients? immune responses for more specific and less toxic cancer therapies, and translate them into clinical practice. To achieve this goal, the Program has three themes: 1) Develop approaches to enhance efficacy of adoptive T cell therapy and cancer vaccines; 2) Modulate the tumor microenvironment to enhance immunotherapy; and 3) Develop novel antibody therapies and imaging modalities. Within each of these themes, research is ongoing to reduce health disparities within our catchment area. Led by Peter Lee, MD and Hua Yu, PhD, the CI Program spans basic, translational, and clinical research. To translate discoveries into therapies, the CI Program receives support from the City of Hope Comprehensive Cancer Center (COHCCC) through the GMP Manufacturing Core, consisting of three cGMP manufacturing facilities that can produce clinical grade antibody-based therapeutics and small molecule drugs. Targeted recruits with national prominence have added both depth and breadth to the program and include Drs. Mingye Feng, Edwin Manuel, Kim Margolin, Laleh Melstrom, Javier Ogembo, Susanne Warner, Yanghee Woo, and Weiping Zou. The major areas of research focus in the CI Program are strengthened by extensive collaborations with other investigators at COHCCC as well as collaborations with investigators at other academic institutions and industry. Sponsored activities include monthly research meetings, monthly seminars, an annual retreat, and annual pilot funding. Membership: 21 Program Members representing 7 basic and clinical departments Publications: 176 total. 18.2% intra-programmatic; 64.8% inter-programmatic; 35.8% inter-institutional Funding: $4,177,832 peer-reviewed; $2,134,027 of which is NCI funding

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beckman Research Institute/City of Hope
United States
Zip Code
Tirughana, Revathiswari; Metz, Marianne Z; Li, Zhongqi et al. (2018) GMP Production and Scale-Up of Adherent Neural Stem Cells with a Quantum Cell Expansion System. Mol Ther Methods Clin Dev 10:48-56
Raz, Dan J; Wu, Geena X; Consunji, Martin et al. (2018) The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low-Dose Computed Tomography. Clin Lung Cancer 19:51-57
Solomon, Ilana; Rybak, Christina; Van Tongeren, Lily et al. (2018) Experience Gained from the Development and Execution of a Multidisciplinary Multi-syndrome Hereditary Colon Cancer Family Conference. J Cancer Educ :
Wang, Dongrui; Aguilar, Brenda; Starr, Renate et al. (2018) Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight 3:
Cheng, Chun-Ting; Qi, Yue; Wang, Yi-Chang et al. (2018) Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction. Commun Biol 1:178
Cho, H; Ayers, K; DePills, L et al. (2018) Modelling acute myeloid leukaemia in a continuum of differentiation states. Lett Biomath 5:S69-S98
Querfeld, Christiane; Leung, Samantha; Myskowski, Patricia L et al. (2018) Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6:900-909
Liu, Xuxiang; Cao, Minghui; Palomares, Melanie et al. (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127
Das, Sadhan; Reddy, Marpadga A; Senapati, Parijat et al. (2018) Diabetes Mellitus-Induced Long Noncoding RNA Dnm3os Regulates Macrophage Functions and Inflammation via Nuclear Mechanisms. Arterioscler Thromb Vasc Biol 38:1806-1820
Al Malki, Monzr M; Nathwani, Nitya; Yang, Dongyun et al. (2018) Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1828-1835

Showing the most recent 10 out of 1396 publications